Expert Review of Cardiovascular Therapy最新文献_第2页

Closing the prevention and diagnosis gap: how can we innovate early coronary heart disease identification in women with female-specific risk factors? 缩小预防和诊断差距：我们如何在具有女性特有危险因素的女性中创新冠心病早期识别？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-23 DOI: 10.1080/14779072.2025.2523929

Eva Sinha, Simone Marschner, Anushriya Pant, Sarah Zaman

引用次数: 0

Bleeding risk assessment tools in patients with atrial fibrillation taking anticoagulants: a comparative review and clinical implications. 房颤患者使用抗凝剂的出血风险评估工具：比较回顾和临床意义。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-23 DOI: 10.1080/14779072.2025.2523920

Chia Siang Kow, Feng Chen, Shawn Leong Kai Jie, Kai Yuan Tham, Li Ann Yeoh, Ze Ming Chew, Wen Jie Peh, Kaeshaelya Thiruchelvam

{"title":"Bleeding risk assessment tools in patients with atrial fibrillation taking anticoagulants: a comparative review and clinical implications.","authors":"Chia Siang Kow, Feng Chen, Shawn Leong Kai Jie, Kai Yuan Tham, Li Ann Yeoh, Ze Ming Chew, Wen Jie Peh, Kaeshaelya Thiruchelvam","doi":"10.1080/14779072.2025.2523920","DOIUrl":"https://doi.org/10.1080/14779072.2025.2523920","url":null,"abstract":"Introduction: Bleeding risk assessment plays a critical role in anticoagulation management for atrial fibrillation (AF), to balance stroke prevention with risk of major hemorrhage. Traditional bleeding risk models, such as HAS-BLED, ORBIT, and ATRIA, offer valuable insights but have limitations in predictive accuracy and clinical applicability. Recent advances in risk stratification have introduced novel models integrating biomarkers, genetic data, and artificial intelligence (AI)-driven algorithms to improve precision and individualized patient care.Areas covered: This review evaluates strengths and limitations of established bleeding risk assessment tools and explores emerging trends in predictive modeling. It discusses novel risk stratification models- DOAC Score, GARFIELD-AF, and HEMORR₂HAGES, which incorporate renal function markers, hematologic parameters, and genetic polymorphisms to enhance predictive accuracy. Integration of machine learning and digital health tools, such as the Universal Clinician Device (UCD) and the mAFA-II mobile application, was also examined for their role in improving anticoagulation safety and adherence.Expert opinion: The future of bleeding risk assessment lies in AI-driven, real-time risk prediction models adapting to dynamic patient profiles. Enhanced integration of digital health solutions and learning health systems will minimize adverse events while optimizing stroke prevention. Future research should prioritize the validation and standardization of these novel tools.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determining major adverse cardiovascular event risk of beta-blocker discontinuation after acute coronary syndromes. 确定急性冠状动脉综合征后β受体阻滞剂停药的主要不良心血管事件风险。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-19 DOI: 10.1080/14779072.2025.2520828

Nicolas Johner, Baris Gencer

{"title":"Determining major adverse cardiovascular event risk of beta-blocker discontinuation after acute coronary syndromes.","authors":"Nicolas Johner, Baris Gencer","doi":"10.1080/14779072.2025.2520828","DOIUrl":"10.1080/14779072.2025.2520828","url":null,"abstract":"Introduction: Beta-blocker therapy reduced mortality and cardiovascular events following acute coronary syndromes (ACS) in the pre-reperfusion era. In the contemporary era of early mechanical reperfusion and modern secondary prevention, the benefit of beta-blockers after ACS without reduced left ventricular ejection fraction (LVEF) has been questioned. This review was based on PubMed database searches from inception to January 2025.Areas covered: The recent REDUCE-AMI and ABYSS trials were the first adequately powered contemporary randomized trials evaluating beta-blockers after ACS without reduced LVEF. Contemporary observational evidence is also discussed. Implications for different LVEF categories (41-49% versus ≥ 50%), ACS subtypes, beta-blocker therapy duration, optimal dose, and interaction with other secondary prevention therapies are addressed.Expert opinion: We estimate that there is sufficient evidence to abandon routine beta-blocker prescription in post-ACS patients with preserved LVEF ≥ 50%. Beta-blocker prescription should be individualized with shared decision-making, balancing the risk of cardiovascular event against potential benefits of deprescription. Factors favoring beta-blocker discontinuation include adverse effects, polypharmacy, >1-3 years of stability post-ACS, and specific comorbidities (e.g. heart failure with preserved LVEF). Factors favoring beta-blocker prescription/continuation (besides established indications such as LVEF ≤ 40%, arrhythmias, angina, and refractory hypertension) include good tolerance, LVEF 41-49%, and non-adherence to other secondary prevention therapies.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":1.8,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence: a promising tool for the clinical cardiologist. 人工智能：临床心脏病专家的一个有前途的工具。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-18 DOI: 10.1080/14779072.2025.2520830

Carlos Escobar, Lorenzo Facila, Rafael Vidal-Pérez, Alberto Pinedo Lapeña, David Vivas, Ana García Martín, Sergio Manzano Fernández, Eva Gonzalez Caballero, Vivencio Barrios, Román Freixa-Pamias

{"title":"Artificial intelligence: a promising tool for the clinical cardiologist.","authors":"Carlos Escobar, Lorenzo Facila, Rafael Vidal-Pérez, Alberto Pinedo Lapeña, David Vivas, Ana García Martín, Sergio Manzano Fernández, Eva Gonzalez Caballero, Vivencio Barrios, Román Freixa-Pamias","doi":"10.1080/14779072.2025.2520830","DOIUrl":"10.1080/14779072.2025.2520830","url":null,"abstract":"Introduction: Artificial intelligence (AI) has emerged as a revolutionary technology that is changing clinical practice, including management of patients with cardiovascular diseases.Areas covered: From a clinical practice perspective, this manuscript reviews the impact of AI on the management of cardiovascular diseases, and current challenges and opportunities. For this purpose, a systematic search was conducted on PubMed (MEDLINE), using the MeSH terms [Artificial intelligence] + [Cardiology] + [Cardiovascular] up to February 2025. Original data from clinical trials, observational studies and reviews of interest were reviewed.Expert opinion: Cardiovascular diseases remain the first cause of morbidity, disability, and death worldwide, mainly owing to late diagnosis, insufficient control of cardiovascular risk factors, and poor use of guideline-recommended therapies. Moreover, the high prevalence of cardiac disease increases stress on the health system, which is already overloaded, challenging its capacity to provide quality patient care. AI-based algorithms may assist clinicians by promoting personalized medicine, improving efficiency, and better anticipating outcomes. Although some AI-based technical solutions are currently implemented, most will be ready for use in the coming years. Nonetheless, many challenges, barriers, and ethical concerns remain, and the effective implementation of AI in routine practice will take some time. In this context, it seems necessary to increase medical knowledge of how AI works, its impact on cardiovascular diseases, and its potential translation to clinical practice.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":1.8,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding endothelial dysfunction in kidney transplantation: assessment techniques, existing evidence, and research needs. 了解肾移植中的内皮功能障碍：评估技术、现有证据和研究需求。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-18 DOI: 10.1080/14779072.2025.2520832

Fotini Iatridi, Eleni Karkamani, Marieta P Theodorakopoulou, Pantelis Sarafidis

{"title":"Understanding endothelial dysfunction in kidney transplantation: assessment techniques, existing evidence, and research needs.","authors":"Fotini Iatridi, Eleni Karkamani, Marieta P Theodorakopoulou, Pantelis Sarafidis","doi":"10.1080/14779072.2025.2520832","DOIUrl":"10.1080/14779072.2025.2520832","url":null,"abstract":"Introduction: Kidney transplant recipients (KTRs) have substantially lower risk for cardiovascular events compared to dialysis, but it remains significantly higher than in the general population due to the synergistic action of traditional and nontraditional factors. Among them, endothelial dysfunction is suggested to be involved pathogenetically in cardiovascular and renal disease progression, with its improvement being another potential benefit of transplantation.Areas covered: VOP was the first technique to be used, followed by several functional methods, most commonly FMD. Over the years, several biomarkers of endothelial dysfunction have been used to assess microvascular function. The totality of evidence in KTRs suggests the improvement of endothelial dysfunction after transplantation, but with several gaps in knowledge, including rarity of studies using novel, more accurate techniques. This review presents the current functional methods and biomarkers used to evaluate microvascular and endothelial function in KTRs, discussing the existing evidence on their changes after transplantation and their associations with comorbidities and outcomes in this population. A comprehensive literature search was conducted in PubMed and Scopus for articles published until December 2024.Expert opinion: Novel methods assessing endothelial function offer a comprehensive, real-time evaluation of microvascular function and should be more widely used to enhance our understanding in this area.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-18"},"PeriodicalIF":1.8,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The overlooked cardiovascular burden of type 1 diabetes: from atherosclerosis to myocardial infarction. 被忽视的1型糖尿病心血管负担：从动脉粥样硬化到心肌梗死。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-18 DOI: 10.1080/14779072.2025.2522223

Jenyfer María Fuentes-Mendoza, Roger Gonzales-Valdivieso, Marcio Concepción-Zavaleta, Maicol Augusto Cortez Sandoval

引用次数: 0

Why low-dose aspirin remains an important antiplatelet in the management of chronic coronary syndromes. 为什么低剂量阿司匹林在慢性冠状动脉综合征治疗中仍然是一种重要的抗血小板药物。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-09 DOI: 10.1080/14779072.2025.2505439

Dirk Sibbing, Augusto María Lavalle Cobo, Zhongwei Shi, Gerhard Albrecht, Li Li

{"title":"Why low-dose aspirin remains an important antiplatelet in the management of chronic coronary syndromes.","authors":"Dirk Sibbing, Augusto María Lavalle Cobo, Zhongwei Shi, Gerhard Albrecht, Li Li","doi":"10.1080/14779072.2025.2505439","DOIUrl":"10.1080/14779072.2025.2505439","url":null,"abstract":"Introduction: Low-dose aspirin has been the cornerstone of single and dual antiplatelet treatment across the cardiovascular risk continuum. It has a well-established efficacy and safety profile, supported by large-scale, placebo-controlled trials as well as long-standing clinical experience. Low-dose aspirin has the highest recommendations in international guidelines for patients with chronic coronary syndromes (CCS), including a lifelong recommendation in patients post vascular interventions and those without prior myocardial infarction or revascularization but with evidence of significant obstructive coronary artery disease.P2Y12 inhibitors - including clopidogrel, ticagrelor, and prasugrel - have recently been explored as an alternatives to low-dose aspirin in patients with CCS, with various trials comparing their efficacy and safety to aspirin.Areas covered: We reviewed the pharmacodynamic and pharmacokinetic properties of low-dose aspirin and P2Y12 inhibitors, data from trials and meta-analyses, and factors that may influence adherence to therapy.Expert opinion: The usefulness and generalizability of the current data on P2Y12 inhibitor monotherapy are limited by a lack of large-scale, multicenter, multiethnic trials. Furthermore, P2Y12 inhibitors lack the evidence for long-term safety and efficacy that are associated with low-dose aspirin. We feel that low-dose aspirin remains a cornerstone therapy in the management of patients with CCS.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-hospital delay and mortality in different age groups with acute coronary syndrome: do we have enough evidence? 不同年龄组急性冠状动脉综合征的院前延误和死亡率：我们有足够的证据吗？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-05-16 DOI: 10.1080/14779072.2025.2505434

Dávid Bauer, Viktor Kočka

{"title":"Pre-hospital delay and mortality in different age groups with acute coronary syndrome: do we have enough evidence?","authors":"Dávid Bauer, Viktor Kočka","doi":"10.1080/14779072.2025.2505434","DOIUrl":"10.1080/14779072.2025.2505434","url":null,"abstract":"Introduction: Pre-hospital delay (p-HD) in acute coronary syndrome (ACS) influences the ability to perform percutaneous coronary intervention in a timely manner. Many factors, including age, have been identified to affect p-HD. An association between different age groups and p-HD in various ACS types is unclear. Moreover, data regarding the relationship between p-HD, age, and mortality are inconsistent.Areas covered: In this review, we present current evidence of how p-HD influences mortality in various age groups and subtypes of ACS. Specific subgroups with knowledge gaps and future perspectives are identified.Expert opinion: We identify specific subgroups of ACS where p-HD affects mortality in different age groups. First, p-HD may significantly affect the long-term prognosis of younger STEMI patients. Second, NSTEMI with known or presumed complex coronary lesions, often related to older age groups, might significantly benefit from p-HD reduction. Third, NSTEMI with ongoing myocardial infarction suffer from considerable p-HD, irrespective of age. These patients might benefit from reduced p-HD by improved education, public awareness, and increased medical service vigilance. Finally, incorporating artificial intelligence (AI) in pre-hospital care may provide further p-HD reduction.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.8,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Secundum atrial septal defects in adults: all you need to know with an emphasis on outcome. 成人二次房间隔缺损：所有你需要知道的重点是结果。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-04-01 Epub Date: 2025-05-02 DOI: 10.1080/14779072.2025.2495235

Qusi Shaban, Ziyad M Hijazi

{"title":"Secundum atrial septal defects in adults: all you need to know with an emphasis on outcome.","authors":"Qusi Shaban, Ziyad M Hijazi","doi":"10.1080/14779072.2025.2495235","DOIUrl":"10.1080/14779072.2025.2495235","url":null,"abstract":"Introduction: Atrial septal defect is the most common congenital heart disease in adults. The secundum defect is the most common anatomical variant. Atrial septal defect usually causes subtle or no symptoms in pediatrics. However, as patients age, the left-to-right shunt increases and more symptoms appear. Atrial septal defect closure is indicated when there is a clinically significant left-to-right shunt, either by echocardiographic data in terms of right-sided dilation, hemodynamic parameters with Qp:Qs ratio over 1.5:1, or the appearance of clinical symptoms.Areas covered: This article reviews secundum atrial septal defects (ASD) with emphasis on device closure outcome in comparison to surgical approaches. The article covers ASD anatomy, pathophysiology, clinical presentation, natural history, imaging evaluation, indications for closure, suitability for transcatheter closure, and outcome of both device closure and surgical closure in the adult patients.Expert opinion: Atrial septal defect closure can be performed either via a transcatheter approach or a surgical approach. The transcatheter approach is preferred worldwide to close secundum ASDs, provided they meet certain anatomical criteria (size and rim sufficiency). The transcatheter approach is more cost-effective, requires a shorter hospital stay, and has similar outcomes with a lower incidence of complications.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"165-178"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac myosin inhibition in hypertrophic cardiomyopathy: review of the evolving evidence base. 肥厚性心肌病的心肌肌球蛋白抑制：不断发展的证据基础的回顾。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-04-01 Epub Date: 2025-05-06 DOI: 10.1080/14779072.2025.2497847

Milind Y Desai, Robert O Bonow

{"title":"Cardiac myosin inhibition in hypertrophic cardiomyopathy: review of the evolving evidence base.","authors":"Milind Y Desai, Robert O Bonow","doi":"10.1080/14779072.2025.2497847","DOIUrl":"10.1080/14779072.2025.2497847","url":null,"abstract":"Introduction: There is an unmet need for effective medical therapies in the treatment of obstructive hypertrophic cardiomyopathy (HCM). This is changing with emergence of cardiac myosin inhibitors (CMI), which reduce cardiac myocyte hypercontractility, normalize left ventricular function, and reduce left ventricular outflow tract obstruction. Mavacamten and aficamten are the first 2 drugs in this class with high-quality phase III randomized clinical trial data (Based on PUBMED search, last query April 2025).Areas covered: In the current review, we perform a detailed analysis of the background characteristics, primary endpoints, efficacy, and safety data available from 4 phase III randomized trials in which mavacamten and aficamten were tested against placebo. This includes understanding clinically meaningful class-based effects vs. specific drug differences.Expert opinion: CMI therapy represents an exciting evolution in management of HCM patients, targeting for the first time the underlying pathophysiologic mechanisms of the disease. There is a growing body of evidence based on high-quality scientific investigation that are broadening the therapeutic options for patients with this condition. However, as different drugs emerge in the same class, it is crucial to appreciate clinically meaningful class-based effects vs. specific drug differences.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"153-163"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0